- Home
- MGIH vs LEXX Comparison
MGIH vs LEXX Comparison
Compare MGIH & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIH
- LEXX
- Stock Information
- Founded
- MGIH 1978
- LEXX 2004
- Country
- MGIH Hong Kong
- LEXX Canada
- Employees
- MGIH N/A
- LEXX N/A
- Industry
- MGIH Publishing
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- MGIH Consumer Discretionary
- LEXX Health Care
- Exchange
- MGIH Nasdaq
- LEXX Nasdaq
- Market Cap
- MGIH 17.3M
- LEXX 19.6M
- IPO Year
- MGIH 2023
- LEXX N/A
- Fundamental
- Price
- MGIH $1.59
- LEXX $0.83
- Analyst Decision
- MGIH
- LEXX Strong Buy
- Analyst Count
- MGIH 0
- LEXX 1
- Target Price
- MGIH N/A
- LEXX $7.00
- AVG Volume (30 Days)
- MGIH 12.1K
- LEXX 143.5K
- Earning Date
- MGIH 07-07-2025
- LEXX 07-11-2025
- Dividend Yield
- MGIH N/A
- LEXX N/A
- EPS Growth
- MGIH N/A
- LEXX N/A
- EPS
- MGIH N/A
- LEXX N/A
- Revenue
- MGIH $28,866,993.00
- LEXX $525,923.00
- Revenue This Year
- MGIH N/A
- LEXX $0.62
- Revenue Next Year
- MGIH N/A
- LEXX $14.19
- P/E Ratio
- MGIH N/A
- LEXX N/A
- Revenue Growth
- MGIH N/A
- LEXX 29.95
- 52 Week Low
- MGIH $1.32
- LEXX $0.82
- 52 Week High
- MGIH $6.83
- LEXX $4.38
- Technical
- Relative Strength Index (RSI)
- MGIH 49.50
- LEXX 31.77
- Support Level
- MGIH $1.52
- LEXX $0.93
- Resistance Level
- MGIH $1.71
- LEXX $1.05
- Average True Range (ATR)
- MGIH 0.09
- LEXX 0.07
- MACD
- MGIH -0.00
- LEXX -0.00
- Stochastic Oscillator
- MGIH 36.00
- LEXX 14.14
About MGIH Millennium Group International Holdings Limited
Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.